Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adicet Bio, Inc. (ACET : NSDQ)

• Company Description    Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $12.90 Daily Weekly Monthly 20 Day Moving Average: 484,616 shares Shares Outstanding: 40.00 (millions) Market Capitalization: $516.06 (millions) Beta: 2.59 52 Week High: $21.17 52 Week Low: $6.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.87% -11.10% 12 Week -5.29% 2.77% Year To Date -26.24% -12.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 BOYLSTON STREET 13TH FLOOR - BOSTON,MA 02116 USA ph: 857-315-5528 fax: - abowdidge@adicetbio.com http://www.adicetbio.com

• General Corporate Information    Officers Chen Schor - President; Chief Executive Officer and Director Nick Harvey - Chief Financial Officer Jeffrey Chodakewitz - Director Steve Dubin - Director Carl L. Gordon - Director Peer Information Adicet Bio, Inc. (CORR.) Adicet Bio, Inc. (RSPI) Adicet Bio, Inc. (CGXP) Adicet Bio, Inc. (BGEN) Adicet Bio, Inc. (GTBP) Adicet Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 007002108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 40.00 Most Recent Split Date: 9.00 (0.14:1) Beta: 2.59 Market Capitalization: $516.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.66 Price/Cash Flow: - Price / Sales: 13.33 EPS Growth vs. Year Ago Period: 112.20% vs. Previous Quarter: 121.28% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 357.02% ROE 03/31/22 - -13.61 12/31/21 - -25.18 09/30/21 - -27.86 ROA 03/31/22 - -11.97 12/31/21 - -21.62 09/30/21 - -22.93 Current Ratio 03/31/22 - 27.07 12/31/21 - 17.31 09/30/21 - 9.94 Quick Ratio 03/31/22 - 27.07 12/31/21 - 17.31 09/30/21 - 9.94 Operating Margin 03/31/22 - -93.18 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - -93.18 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -93.38 12/31/21 - -638.48 09/30/21 - -572.82 Book Value 03/31/22 - 7.78 12/31/21 - 9.49 09/30/21 - 6.82 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©